Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph Gligorov

Showing results (1-10 of 184) with videos related to

Pageof 19
Sort By:
The Lancet. Oncology|November 28, 2017
Early HER2-positive breast cancers: time for a new revolution?Joseph Gligorov
The Lancet. Oncology|February 2, 2015
Looking for predictive markers in breast cancer--authors' replyJoseph Gligorov
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 5, 2009
Concurrent trastuzumab--internal mammary irradiation for HER2 positive breast cancer: "It hurts to be on the cutting edge"Yazid Belkacémi, Joseph Gligorov
Nature Reviews. Clinical Oncology|August 12, 2015
Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBCJoseph Gligorov, Sandrine Richard
Bulletin Du Cancer|June 13, 2003
[From San Antonio to Saint-Gallen: reflections of Saint-Paul-de-Venice or how to treat breast cancer]Joseph Gligorov, Philippe Beuzeboc
Clinical Nuclear Medicine|May 18, 2026
Functional Estrogen Receptor Assessment: Insights From Discordant 18F-FES PET/CT and ER ImmunohistochemistryKhaldoun Kerrou, Joseph Gligorov
Reviews on Recent Clinical Trials|May 14, 2008
The emerging role of aromatase inhibitors in the adjuvant management of breast cancerJean-Marc Nabholtz, Joseph Gligorov
Expert Opinion on Pharmacotherapy|August 10, 2005
Docetaxel/trastuzumab combination therapy for the treatment of breast cancerJean-Marc Nabholtz, Joseph Gligorov
Breast Cancer Research and Treatment|December 23, 2008
Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancerJoseph Gligorov, Jean-Pierre Lotz
The Oncologist|May 27, 2004
Preclinical pharmacology of the taxanes: implications of the differencesJoseph Gligorov, Jean Pierre Lotz
Pageof 19

Showing results (1-10 of 184) with videos related to

Sort By:
Pageof 19
The Lancet. Oncology|November 28, 2017
Early HER2-positive breast cancers: time for a new revolution?Joseph Gligorov
The Lancet. Oncology|February 2, 2015
Looking for predictive markers in breast cancer--authors' replyJoseph Gligorov
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 5, 2009
Concurrent trastuzumab--internal mammary irradiation for HER2 positive breast cancer: "It hurts to be on the cutting edge"Yazid Belkacémi, Joseph Gligorov
Nature Reviews. Clinical Oncology|August 12, 2015
Breast cancer: weekly paclitaxel--still preferred first-line taxane for mBCJoseph Gligorov, Sandrine Richard
Bulletin Du Cancer|June 13, 2003
[From San Antonio to Saint-Gallen: reflections of Saint-Paul-de-Venice or how to treat breast cancer]Joseph Gligorov, Philippe Beuzeboc
Clinical Nuclear Medicine|May 18, 2026
Functional Estrogen Receptor Assessment: Insights From Discordant 18F-FES PET/CT and ER ImmunohistochemistryKhaldoun Kerrou, Joseph Gligorov
Reviews on Recent Clinical Trials|May 14, 2008
The emerging role of aromatase inhibitors in the adjuvant management of breast cancerJean-Marc Nabholtz, Joseph Gligorov
Expert Opinion on Pharmacotherapy|August 10, 2005
Docetaxel/trastuzumab combination therapy for the treatment of breast cancerJean-Marc Nabholtz, Joseph Gligorov
Breast Cancer Research and Treatment|December 23, 2008
Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancerJoseph Gligorov, Jean-Pierre Lotz
The Oncologist|May 27, 2004
Preclinical pharmacology of the taxanes: implications of the differencesJoseph Gligorov, Jean Pierre Lotz
Pageof 19